Palbociclib and Letrozole in Advanced Breast CancerRichard S. Finn, Dennis J. Slamon, Eric Gauthier et al.|New England Journal of Medicine|2016Cited by 2.9k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Makoto Ueno et al.|The Lancet|2023Cited by 1k
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero et al.|Journal of Hepatology|2020Cited by 421
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibitionHabib Hamidi, Richard S. Finn|British Journal of Cancer|2014Cited by 53